Nichols, Charles D

Louisiana State University Health Sciences Center, New Orleans

Affiliations

School of Medicine

Department Of Pharmacology

Louisiana State University Health Sciences Center, New Orleans

Charles D. Nichols is a High Senior Professor at Louisiana State University Health Sciences Center, New Orleans. His research integrates pharmacology, neuropsychopharmacology, and biological psychiatry, focusing on the molecular mechanisms of psychoactive drugs, particularly 5-HT2A receptor pharmacology and functional selectivity. His recent work explores psychedelics as rapid-acting antidepressants and anti-inflammatory agents, including the development of novel selective agonists like LPH-5, and the application of AI-driven protein-ligand modeling to psychedelic compounds. He also investigates serotonin-immune interactions and receptor-mediated behavioral plasticity, with publications in Neuropsychopharmacology and Pharmacological Reviews.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Nichols, Charles D

Louisiana State University Health Sciences Center, New Orleans

You can click a keyword to filter the displayed items

pharmacology neuroscience neuropharmacology neuropsychopharmacology receptors psychopharmacology behavioral neuroscience psychiatry pharmacological research biological psychiatry insect molecular biology psychoactive drugs genetics drug discovery nervous system inflammation psychopathology molecular psychiatry neurotransmitters developmental system respiratory medicine medicinal research gene expression molecular physiology behavioural pharmacology psychiatric research developmental genetics neurochemistry psychotropic medication neurobiological mechanisms dopamine pharmacotherapy molecular neurodegeneration insect biochemistry receptor (biochemistry) animal cognition experimental medicine neuropsychiatry molecular neurobiology inflammatory diseases anti-inflammatory behavioral neuroendocrinology signaling pathways drosophila melanogaster genome biology pharmacokinetics gene function neuroendocrine mechanisms energy homeostasis g protein-coupled receptor respiratory neurobiology brain science psychedelic drugs drosophila eye development prefrontal cortex adipocyte differentiation tnf-a mediated inflammation experimental analysis of behavior scientific visualization experimental pharmacology clinical pharmacology genomic mechanisms rna biology geriatric medicine later adulthood biological psychology human disease models therapeutic drug discovery anti-inflammatory agents future research extraordinary potency stress granules rna-binding ability als-linked mutations cytoplasmic mislocalization rodent experimental system

Notable Scholarly Works

Notable Federal Grants

Collaborators

Assessing Modern AI-Driven Protein-Ligand Modeling With Phenethylamine and Tryptamine Psychedelics. AI Chemistry (2026)

tryptamine psychedelicscomputational biologyprotein sciencedrug targetscomputational chemistryprotein modelingbiochemistrypeptidesmolecular informaticsrational drug designsystems biologypharmacological researchmolecular dockingdrug discovery

5-Ht2A Receptors: Pharmacology and Functional Selectivity. Pharmacological Reviews (2025)

pharmacological researchreceptorsfunctional selectivitypharmacology

History of Psychedelic Drug Science and Molecular Pharmacology. International review of neurobiology (2025)

neuropharmacologyneurosciencepharmacologymolecular pharmacologypharmacological researchpsychoactive drugs

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats. Psychedelic Medicine (2025)

lorazepam negatespsychiatryneuropharmacologybiological psychiatrypsychotropic medicationneuropsychopharmacologylong-term antidepressant-like effectsbehavioural pharmacologypharmacologypsychopharmacologypsychopathologypharmacological researchdepressionpsychoactive drugs

Psychedelic Research Must Be Grounded in Pharmacology. Nature Neuroscience (2025)

Psychedelics Produce Enduring Behavioral Effects and Functional Plasticity Through Mechanisms Independent of Structural Plasticity. Neuropsychopharmacology (2025)

behavioural processneuropharmacologyfunctional plasticitybehavioral effectsaddiction biologyneuropsychopharmacologybehavioral neuroscienceneurosciencestructural plasticitybehavioural pharmacologypsychopharmacologyaffective neurosciencepsychoactive drugsbehavioral sciences

Serotonin, Immune Function, and Psychedelics as Potent Anti-Inflammatories. International review of neurobiology (2025)

immune functionneuropharmacologybiological psychiatryneuropsychopharmacologypharmacologypsychopharmacologypharmacological researchpsychoactive drugs

The Selective Serotonin 5-Ht 2A Receptor Agonist ( S )-3-(2,5-Dimethoxy-4-(Trifluoromethyl)Phenyl)Piperidine (Lph-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents. ACS Pharmacology & Translational Science (2025)

psychiatryneuropharmacologybiological psychiatrypsychotropic medicationinduces persistentneuropsychopharmacologyneurosciencerobust antidepressant-like effectspharmacologypsychopharmacologypharmacological researchmolecular psychiatrydepression

Us Drug Policy Does Not Align With Experts’ Rankings of Drug Harms: A Multi-Criteria Decision Analysis. Harm Reduction Journal (2025)

health policyharm reductiondrug policysubstance abuse

Using Uas-Gal4 Designer Receptors Exclusively Activated by Designer Drugs to Elucidate Nondopaminergic Modulation of Methamphetamine-Induced Locomotion in Drosophila. Behavioural Pharmacology (2025)

molecular neuroscienceinsect molecular biologydesigner drugsnondopaminergic modulationneuropharmacologyuas-gal4 designer receptorsneuronsaddiction biologyneuropsychopharmacologyneurosciencedopaminefunctional selectivitypharmacologynervous systemmolecular pharmacologyneurotransmitterspharmacological researchreceptors